Skip to main content
GRDNGuardian Pharmacy Services, IncHold5.7·$50.33
HoldModerate Confidence
Investment thesis

Guardian Pharmacy has a perfect four-quarter beat streak, ROE of 32% and strong momentum near its 52-week high, but the price of $49.52 is 11.9% above the analyst target, revenue is declining 2% and one customer group drives the business.

Thesis pillars

  • High Return On Equity→Stable
  • Perfect Earnings Beat Streak↓Deteriorating
  • Price Above Analyst Target→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 14, 2026, based on the 10-K filed Mar 11, 2026

Full reasoning →

Open full analysis

Guardian Pharmacy Services, Inc (GRDN) Stock Analysis

HoldGrowthQualityShortModerate Confidence

Healthcare · Medical Care Facilities

Hold if already holding. Not a fresh buy at $50.33, but acceptable to hold if already in. Reasons: Concentration risk — Customer: ALF and BHF residents; Analyst target reached - limited upside remaining.

Guardian Pharmacy Services operates 61 pharmacies serving 205,000 residents in 8,400 long-term care facilities across 38 states, generating over two-thirds of revenue from assisted living and behavioral health facilities. Revenue comes from prescription dispensing reimbursed by... Read more

$50.33-11.3% A.UpsideScore 5.7/10#12 of 35 Medical Care Facilities
QualityF-score7 / 9FCF yield2.37%
Stop $46.81Analyst target $44.62(reached)A.R:R -0.8:1
Analyst consensus$51.29+1.9%7 analysts with price targets
$50.33price
$51.29mean
$49
$55

Hold if already holding. Not a fresh buy at $50.33, but acceptable to hold if already in. Reasons: Concentration risk — Customer: ALF and BHF residents; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 113d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About Guardian Pharmacy Services, Inc

About Guardian Pharmacy Services, Inc

Guardian Pharmacy Services' 61 pharmacies — 54 full-service — served approximately 205,000 residents across about 8,400 long-term care facilities in 38 states at December 31, 2025, generating more than two-thirds of annual revenue from assisted living facilities (ALFs) and behavioral health facilities (BHFs). The U.S. institutional pharmacy market was estimated at approximately $24.3 billion for 2025 by IBISWorld, with Guardian claiming roughly 13.0% national market share in ALF and memory care settings.

Guardian earns revenue through prescription dispensing reimbursed by Medicare Part D, Medicaid, and commercial health plans, adjudicating every prescription and assisting residents in optimizing pharmacy benefit plan coverage. The company deploys over 100 automated robotic dispensing machines across its pharmacy network, integrates with facility Electronic Medication Administration Records (EMARs), and offers compliance packaging, pharmacist consultations, and clinical analytics programs under the GuardianShield platform. The competitive landscape includes two national providers historically focused on skilled nursing facilities (SNFs), several regional providers, and over 1,200 independent pharmacies. The ALF sector presents specific operational challenges that favor specialized providers: residents typically carry multiple pharmacy benefit plans with distinct formularies, facilities often lack on-site medical directors, and residents have the right to choose their own pharmacy.

Show full overview

Reimbursement risk is the primary financial exposure. Guardian's revenue depends substantially on Medicare Part D and Medicaid rates, which are subject to federal and state rate-setting cycles. The 10-K identifies ongoing government and private efforts to limit pharmacy reimbursements as a material risk factor, and flags consolidation of managed care organizations as a structural headwind that could alter payor agreement terms unfavorably. With operations spanning 38 states, the company is exposed to varied state Medicaid fee schedules; any compression in reimbursement rates paid by health plan payors could reduce revenue per prescription without a corresponding reduction in dispensing cost.

See also: Healthcare · Medical Care Facilities

From Guardian Pharmacy Services, Inc's most recent 10-K filing, extracted June 10, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 4, 2026

Recent Developments — Guardian Pharmacy Services, Inc

Latest item Nov 4, 2026 · Generated 2026-11-18T11:47:23Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 11, 2027113d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Positive insider activity
Recent Analyst detected in news
Risks
Concentration risk — Customer: ALF and BHF residents
Analyst target reached - limited upside remaining
Near 52-week high (0.9% away)

Key Metrics

P/E (TTM)43.0
P/E (Fwd)33.5
Mkt Cap$3.2B
EV/EBITDA26.5
Profit Mgn5.1%
ROE32.0%
Rev Growth-1.7%
Beta0.06
DividendNone
Analysts with ratings13

Quality Signals

Piotroski F7/9MoatNarrow

Options Flow

IV70%elevated

Concentration Risks(10-K Item 1A)

  • HIGHCustomerALF and BHF residents
    10-K Item 1: 'More than two-thirds of our annual revenue for each of the past three years has been generated from residents of ALFs and BHFs'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
0.4
Bollinger
1.2
52w Position
9.8
GatesA.R:R -0.8=NEGATIVEMomentum 5.0<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.0>=4.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.50EARNINGS PROXIMITY 113d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
79 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $38.85Resistance $50.80

Price Targets

A.Upside-11.3%
A.R:R-0.8:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCautious

Risk Alerts

! Target reached (-11.3% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-03-11 (113d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is GRDN stock a buy right now?

Hold if already holding. Not a fresh buy at $50.33, but acceptable to hold if already in. Reasons: Concentration risk — Customer: ALF and BHF residents; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $44.62 reached (−11.3%), stop $46.81 (−7.5%), A.R:R -0.8:1. Score 5.7/10, moderate confidence.

What is the GRDN stock price target?

Analyst target $44.62 reached (−11.3% from $50.33); no take-profit level is published. Analyst target $44.62 reached (−11.3%), stop $46.81 (−7.5%), A.R:R -0.8:1. Stop-loss: $46.81.

What are the risks of investing in GRDN?

Concentration risk — Customer: ALF and BHF residents; Analyst target reached - limited upside remaining; Near 52-week high (0.9% away).

Is GRDN overvalued or undervalued?

Guardian Pharmacy Services, Inc trades at a P/E of 43.0 (forward 33.5). TrendMatrix value score: 4.8/10. Verdict: Hold.

What do analysts say about GRDN?

13 analysts rate GRDN, with a consensus score of 4.4/5. 7 analysts publish price targets averaging $51.

What does Guardian Pharmacy Services, Inc do?Guardian Pharmacy Services operates 61 pharmacies serving 205,000 residents in 8,400 long-term care facilities across...

Guardian Pharmacy Services operates 61 pharmacies serving 205,000 residents in 8,400 long-term care facilities across 38 states, generating over two-thirds of revenue from assisted living and behavioral health facilities. Revenue comes from prescription dispensing reimbursed by Medicare, Medicaid, and commercial health plans. The company holds approximately 13.0% national market share in ALF and memory care pharmacy.

Related stocks: AVAH (Aveanna Healthcare Holdings Inc) · SRTA (Strata Critical Medical, Inc.) · NUTX (Nutex Health Inc.) · ARDT (Ardent Health, Inc.) · DVA (DaVita Inc.)
Home › Stocks › GRDN

Latest news

Latest News

TradingKey112d ago
TradingKey112d ago
Yahoo Finance203d agoEarnings
Investing.com154d agoAnalyst
TradingView154d agoAnalyst
Moomoo154d agoAnalyst
Marketscreener.com154d agoAnalyst
TradingKey154d ago
TradingKey154d ago
AOL.com196d agoEarnings
KING5.com196d agoEarnings
KVUE196d agoEarnings
Investing.com Canada196d agoEarnings
Yahoo Finance105d agoEarnings
Yahoo Finance14d agoEarnings
Simply Wall St22d agoEarnings
Cổng thông tin điện tử tỉnh Lào Cai211d ago
MarketBeat99d ago
Simplywall.st99d ago
The Lane Report106d ago
Loading more...